SG Americas Securities LLC Invests $119,000 in Vera Therapeutics, Inc. (NASDAQ:VERA)

SG Americas Securities LLC bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 7,709 shares of the company’s stock, valued at approximately $119,000.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Vera Therapeutics by 9.3% during the third quarter. Vanguard Group Inc. now owns 1,574,390 shares of the company’s stock worth $21,585,000 after buying an additional 134,125 shares in the last quarter. Citigroup Inc. grew its holdings in shares of Vera Therapeutics by 470.0% in the third quarter. Citigroup Inc. now owns 57,390 shares of the company’s stock valued at $787,000 after purchasing an additional 47,322 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Vera Therapeutics in the third quarter valued at about $1,159,000. Deutsche Bank AG grew its holdings in shares of Vera Therapeutics by 16.7% in the third quarter. Deutsche Bank AG now owns 16,031 shares of the company’s stock valued at $220,000 after purchasing an additional 2,289 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of Vera Therapeutics in the third quarter valued at about $411,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on VERA. Raymond James raised shares of Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $29.00 to $37.00 in a report on Friday, January 26th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Vera Therapeutics in a research report on Wednesday, December 27th. Oppenheimer started coverage on shares of Vera Therapeutics in a research report on Thursday, January 25th. They issued an “outperform” rating and a $26.00 target price on the stock. Wedbush upped their target price on shares of Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a research report on Thursday, March 21st. Finally, Cantor Fitzgerald started coverage on shares of Vera Therapeutics in a research report on Monday, January 8th. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Vera Therapeutics has an average rating of “Buy” and a consensus price target of $32.29.

Insider Buying and Selling

In related news, SVP Joseph R. Young sold 5,714 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total transaction of $228,560.00. Following the sale, the senior vice president now directly owns 53,171 shares in the company, valued at $2,126,840. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Joseph R. Young sold 5,714 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total transaction of $228,560.00. Following the sale, the senior vice president now directly owns 53,171 shares in the company, valued at $2,126,840. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Maha Katabi sold 340,000 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $40.50, for a total transaction of $13,770,000.00. Following the sale, the director now owns 2,793,987 shares in the company, valued at $113,156,473.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 526,551 shares of company stock worth $21,533,345. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Stock Down 1.3 %

Shares of VERA opened at $39.48 on Friday. The stock has a market capitalization of $2.15 billion, a PE ratio of -17.24 and a beta of 1.05. Vera Therapeutics, Inc. has a 1 year low of $6.07 and a 1 year high of $50.78. The company has a debt-to-equity ratio of 0.49, a quick ratio of 7.71 and a current ratio of 7.71. The company’s 50-day simple moving average is $43.76 and its 200-day simple moving average is $25.75.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.05). Analysts forecast that Vera Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.